Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Interpace BiosciencesIDXG +2.55%41 PB Ratio is 1.92 as of Aug. 20, 2026, which is 129% above its 10-year median of 0.84. GuruFocus rates IDXG with a GF Score™ of 41/100 and a GF Value™ of $0.20 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 193 Medical Diagnostics & Research companies, Interpace Biosciences ranks better than 56.99% on this metric.
The historical rank and industry rank for Interpace Biosciences's PB Ratio or its related term are showing as below:
IDXG'
s PB Ratio Range Over the Past 10 Years
Min: 0.22 Med: 0.84 Max: 15.18
Current: 1.92
During the past 13 years, Interpace Biosciences's highest PB Ratio was 15.18. The lowest was 0.22. And the median was 0.84.
IDXG's PB Ratio is ranked better than 56.99% of 193
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.24
vs IDXG: 1.92
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Interpace Biosciences was 63.20% per year. The lowest was -134.20% per year. And the median was -20.70% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Interpace Biosciences's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Interpace Biosciences PB Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Interpace Biosciences's PB Ratio distribution charts can be found below:
* The bar in red indicates where Interpace Biosciences's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Interpace Biosciences (IDXG) has a PB Ratio of 1.92 as of Aug. 20, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Interpace Biosciences and its competitors. This is 129% above median its historical median of 0.84. Over the past decade, Interpace Biosciences' PB Ratio has ranged from 0.22 to 15.18. According to the industry distribution chart, Interpace Biosciences ranks #83 out of 193 companies in the Medical Diagnostics & Research industry, placing it in the top 43%.
Is Interpace Biosciences' PB Ratio too high?
Interpace Biosciences' current PB Ratio of 1.92 is 129% above median its 10-year median of 0.84. Over the past 10 years, this metric has ranged from a low of 0.22 to a high of 15.18. The Medical Diagnostics & Research industry median PB Ratio is 2.24. Interpace Biosciences' value of 1.92 is 14.3% below this industry median. Based on the distribution chart, Interpace Biosciences ranks #83 out of 193 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Interpace Biosciences has a GF Score™ of 41/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Interpace Biosciences' PB Ratio compare to PRPO and ADVB?
According to the Medical Diagnostics & Research industry distribution chart, Interpace Biosciences ranks #83 out of 193 companies for PB Ratio. This puts Interpace Biosciences in the upper half of its industry. The industry median PB Ratio is 2.24. Interpace Biosciences' value of 1.92 is 14.3% below this benchmark. Historically, Interpace Biosciences' own PB Ratio has ranged from 0.22 to 15.18 over the past decade. While the company's 10-year median is 0.84 vs. the industry median of 2.24, Interpace Biosciences has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Medical Diagnostics & Research company?
The median PB Ratio among Medical Diagnostics & Research companies is 2.24, based on 193 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Interpace Biosciences's current PB Ratio of 1.92 is 14.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Interpace Biosciences and its competitors. For the Medical Diagnostics & Research industry, the median PB Ratio is 2.24 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Interpace Biosciences's current PB Ratio is 1.92, which is 129% above median its own 10-year median of 0.84. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Interpace Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Interpace Biosciences (IDXG) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.20, compared to a current price of $1.61 — trading 705% above its estimated fair value. The current PB Ratio is 1.92, which is 129% above median its 10-year median of 0.84 and 14.3% below the Medical Diagnostics & Research industry median of 2.24. Interpace Biosciences' overall GF Score™ is 41/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Interpace Biosciences (IDXG), the current PB Ratio is 1.92 as of Aug. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Interpace Biosciences (IDXG) Overvalued in 2026?
Based on GuruFocus' analysis, Interpace Biosciences stock appears to be overvalued.
The current stock price of $1.61 is trading 705% above its estimated GF Value™ of $0.20.
GuruFocus considers Interpace Biosciences to be Significantly Overvalued.
Key valuation signals for IDXG:
PB Ratio: 1.92 (129% above median its 10-year median of 0.84)
GF Value™: $0.20 vs. price of $1.61 (705% above fair value)
Industry Position: 14.3% below the Medical Diagnostics & Research median (#83 of 193)
No single metric tells the full story. See the IDXG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Interpace Biosciences Inc provides esoteric molecular diagnostic testing and pathology services to aid physicians in evaluating cancer risk in patients with indeterminate biopsies and a perceived high risk of cancer based on clinical features. The company develops and commercializes genomic tests and related first-line assays that can personalize medicine and help improve patient diagnosis and management. Its clinical customers mainly consist of physicians, hospitals, cancer centers, commercial laboratories, pathology groups, and clinics. The various diagnostic tests offered by the company include ThyGeNEXT and ThyraMIRv2 for the detection of thyroid cancer.
41GF Score
Get the complete analysis for IDXG
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IDXG has been successfully added to your 
